Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure

The impact of body mass index (BMI) on treatment outcomes in patients with cancer is gaining increasing attention given the limited data available. The aim of this study was to investigate the contribution of BMI on the safety and efficacy profile of palbociclib in 134 patients with metastatic lumin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedicine & pharmacotherapy 2023-08, Vol.164, p.114906-114906, Article 114906
Hauptverfasser:	Roncato, Rossana, Peruzzi, Elena, Gerratana, Lorenzo, Posocco, Bianca, Nuzzo, Sofia, Montico, Marcella, Orleni, Marco, Corsetti, Serena, Bartoletti, Michele, Gagno, Sara, Canil, Giovanni, De Mattia, Elena, Angelini, Jacopo, Baraldo, Massimo, Puglisi, Fabio, Cecchin, Erika, Toffoli, Giuseppe
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Body Mass Index Breast Neoplasms - pathology Female HER-negative breast cancer Hormon receptor-positive Humans Palbociclib Progression free survival Receptor, ErbB-2 Treatment adherence Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The impact of body mass index (BMI) on treatment outcomes in patients with cancer is gaining increasing attention given the limited data available. The aim of this study was to investigate the contribution of BMI on the safety and efficacy profile of palbociclib in 134 patients with metastatic luminal-like breast cancer treated with palbociclib and endocrine therapy (ET). Normal-weight and underweight patients (BMI
ISSN:	0753-3322 1950-6007
DOI:	10.1016/j.biopha.2023.114906